PM-477 

First-in-class synthetic lysin

Medical need:

Bacterial vaginosis

image49.png
phagomedElement 22300.png
phagomedElement 22300.png
phagomedElement.png
phagomedElement 1.png

High efficacy,

high precision

Pathogen:

Gardnerella spp.

Patient population:

1 in 4 women (aged 15-49) p.a. globally

Recurrence:

60% within 6 months

Current standard-of-care:

Broad-spectrum antibiotics (acute) and long-term suppressive antibiotics (chronic)

Cleaving domain

PM-477 has a cleaving domain. After it binds to the cell wall, it lyses it. The cell bursts and the bacteria die.

image27_edited.png
image28_edited.png

Binding domain

PM-477 has a Gardnerella specific binding domain. It only binds to the cell wall of Gardnerella bacteria. It is specific.

PM-477

Target pathogen: Gardnerella spp.

Indication: recurrent bacterial vaginosis

Discovery

Lead optimization

Pre-clinical

Phase I

Phase II

pm-477 thumbnail

Read our Publication in Pathogens

The first publication detailing PM-477 is now available.  

Scientific Advisory Board

Prof. Dr. med. Werner Mendling

Prof. Dr. Christina Muzny

Dr. Gregory Resch

Prof. Dr. Jane Schwebke

Prof. Dr. Jack Sobel

PD Dr. Alexander Swidsinski

Prof. Dr. Mario Vaneechoutte